Teva announces $2,000,000,000 (equivalent) debt tender offers for notes due 2026-2031

Tel aviv, israel, may 19, 2025 (globe newswire) -- teva pharmaceutical industries ltd. (nyse and tase: teva) (“teva”) announced today that it has commenced tender offers (the “offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) (the “total maximum amount”) of the following series of notes issued by finance subsidiaries of teva and guaranteed by teva:
TEVA Ratings Summary
TEVA Quant Ranking